Class information for: |
Basic class information |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Terms with highest relevance score |
rank | Category | termType | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|---|
1 | GEFITINIB | authKW | 795912 | 5% | 52% | 807 |
2 | EGFR | authKW | 747355 | 9% | 26% | 1503 |
3 | EPIDERMAL GROWTH FACTOR RECEPTOR | authKW | 697675 | 7% | 31% | 1189 |
4 | ERLOTINIB | authKW | 572712 | 4% | 46% | 655 |
5 | EGFR MUTATION | authKW | 496984 | 2% | 66% | 393 |
6 | NEUREGULIN | authKW | 269496 | 2% | 55% | 259 |
7 | NON SMALL CELL LUNG CANCER | authKW | 234195 | 7% | 11% | 1133 |
8 | AFATINIB | authKW | 221504 | 1% | 70% | 166 |
9 | ERBB4 | authKW | 215385 | 1% | 69% | 163 |
10 | NEUREGULIN 1 | authKW | 199825 | 1% | 67% | 156 |
Web of Science journal categories |
chi_square_rank | Category | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | Oncology | 106231 | 42% | 1% | 6941 |
2 | Cell Biology | 9398 | 14% | 0% | 2296 |
3 | Respiratory System | 5495 | 5% | 0% | 883 |
4 | Biochemistry & Molecular Biology | 5049 | 18% | 0% | 3039 |
5 | Pathology | 3028 | 4% | 0% | 731 |
6 | Chemistry, Medicinal | 1348 | 3% | 0% | 570 |
7 | CYTOLOGY & HISTOLOGY | 1212 | 0% | 1% | 73 |
8 | Pharmacology & Pharmacy | 953 | 7% | 0% | 1179 |
9 | Gastroenterology & Hepatology | 761 | 3% | 0% | 464 |
10 | Medicine, Research & Experimental | 702 | 4% | 0% | 610 |
Address terms |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | GUANGDONG LUNG CANC | 49064 | 0% | 36% | 72 |
2 | MED ONCOL | 45119 | 7% | 2% | 1103 |
3 | THORAC ONCOL | 39658 | 1% | 10% | 217 |
4 | LOWE THORAC ONCOL | 35398 | 0% | 32% | 59 |
5 | THORAC ONCOL SERV | 30159 | 0% | 27% | 58 |
6 | RADIOBIOL MOL ENVIRONM | 21244 | 0% | 45% | 25 |
7 | ONCOL | 19224 | 5% | 1% | 902 |
8 | CANC DRUG | 18941 | 0% | 76% | 13 |
9 | PATHOL | 15714 | 13% | 0% | 2079 |
10 | CANC | 15197 | 5% | 1% | 802 |
Journals |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | JOURNAL OF THORACIC ONCOLOGY | 59889 | 2% | 11% | 296 |
2 | LUNG CANCER | 48397 | 2% | 8% | 342 |
3 | CLINICAL LUNG CANCER | 27500 | 1% | 13% | 111 |
4 | CLINICAL CANCER RESEARCH | 14208 | 2% | 2% | 344 |
5 | ONCOTARGETS AND THERAPY | 8442 | 1% | 5% | 100 |
6 | GROWTH FACTORS | 7838 | 0% | 7% | 58 |
7 | TARGETED ONCOLOGY | 7395 | 0% | 9% | 42 |
8 | ONCOTARGET | 5950 | 1% | 1% | 233 |
9 | CANCER RESEARCH | 5556 | 2% | 1% | 356 |
10 | THORACIC CANCER | 4906 | 0% | 7% | 38 |
Author Key Words |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass | LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | GEFITINIB | 795912 | 5% | 52% | 807 | Search GEFITINIB | Search GEFITINIB |
2 | EGFR | 747355 | 9% | 26% | 1503 | Search EGFR | Search EGFR |
3 | EPIDERMAL GROWTH FACTOR RECEPTOR | 697675 | 7% | 31% | 1189 | Search EPIDERMAL+GROWTH+FACTOR+RECEPTOR | Search EPIDERMAL+GROWTH+FACTOR+RECEPTOR |
4 | ERLOTINIB | 572712 | 4% | 46% | 655 | Search ERLOTINIB | Search ERLOTINIB |
5 | EGFR MUTATION | 496984 | 2% | 66% | 393 | Search EGFR+MUTATION | Search EGFR+MUTATION |
6 | NEUREGULIN | 269496 | 2% | 55% | 259 | Search NEUREGULIN | Search NEUREGULIN |
7 | NON SMALL CELL LUNG CANCER | 234195 | 7% | 11% | 1133 | Search NON+SMALL+CELL+LUNG+CANCER | Search NON+SMALL+CELL+LUNG+CANCER |
8 | AFATINIB | 221504 | 1% | 70% | 166 | Search AFATINIB | Search AFATINIB |
9 | ERBB4 | 215385 | 1% | 69% | 163 | Search ERBB4 | Search ERBB4 |
10 | NEUREGULIN 1 | 199825 | 1% | 67% | 156 | Search NEUREGULIN+1 | Search NEUREGULIN+1 |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Classes with closest relation at Level 2 |